- Home
- MCB vs DNTH Comparison
MCB vs DNTH Comparison
Compare MCB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCB
- DNTH
- Stock Information
- Founded
- MCB 1999
- DNTH 2015
- Country
- MCB United States
- DNTH United States
- Employees
- MCB N/A
- DNTH N/A
- Industry
- MCB Major Banks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- MCB Finance
- DNTH Health Care
- Exchange
- MCB Nasdaq
- DNTH Nasdaq
- Market Cap
- MCB 693.0M
- DNTH 565.7M
- IPO Year
- MCB 2017
- DNTH N/A
- Fundamental
- Price
- MCB $59.56
- DNTH $21.56
- Analyst Decision
- MCB Buy
- DNTH Strong Buy
- Analyst Count
- MCB 3
- DNTH 8
- Target Price
- MCB $76.33
- DNTH $54.33
- AVG Volume (30 Days)
- MCB 133.8K
- DNTH 425.0K
- Earning Date
- MCB 04-21-2025
- DNTH 05-08-2025
- Dividend Yield
- MCB N/A
- DNTH N/A
- EPS Growth
- MCB N/A
- DNTH N/A
- EPS
- MCB 5.92
- DNTH N/A
- Revenue
- MCB $270,555,000.00
- DNTH $6,235,000.00
- Revenue This Year
- MCB $9.44
- DNTH N/A
- Revenue Next Year
- MCB $13.96
- DNTH N/A
- P/E Ratio
- MCB $9.97
- DNTH N/A
- Revenue Growth
- MCB 12.84
- DNTH 120.63
- 52 Week Low
- MCB $37.10
- DNTH $13.37
- 52 Week High
- MCB $69.56
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- MCB 64.74
- DNTH 60.32
- Support Level
- MCB $53.80
- DNTH $18.65
- Resistance Level
- MCB $53.75
- DNTH $19.76
- Average True Range (ATR)
- MCB 3.24
- DNTH 2.04
- MACD
- MCB 1.07
- DNTH 0.71
- Stochastic Oscillator
- MCB 91.50
- DNTH 79.36
About MCB Metropolitan Bank Holding Corp.
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.